The latest report from Growth Plus Reports analyzes the production, applications, demand, major manufacturers, and SWOT analysis of the global asthma & COPD drugs market.
Asthma & COPD drugs market research report assists in finalizing the best distribution methods for certain products and markets for new products. You can get insights into TOC, Tables, and Charts presented throughout the report for valuable data, information, important statistics, trends, and detailed competitive landscape information in this market.
Key Takeaways:
- The growth in air pollution will drive market revenue growth.
- The increasing number of asthma and COPD patients will drive demand for asthma & COPD drugs.
- North America dominates global asthma & COPD drugs market.
Download PDF Brochure of Asthma & COPD Drugs Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/asthma-copd-drugs-market/7909
Asthma & COPD Drugs Market Scope
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 33 billion |
|
Revenue forecast in 2030 |
US$ 51.3 billion |
|
Growth Rate |
CAGR of 4.5% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
by disease type, drug class, distribution channel, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Market Drivers
An aging population and increased amounts of industrial and automotive exhaust gas will drive the revenue growth of asthma & COPD drugs market. Furthermore, the increasing prevalence of asthma due to decreased air quality around industrial zones is expected to boost the market revenue growth rate. Rising disposable income levels will also likely support the market’s revenue growth.
Market Segmentation
Growth Plus Reports has analyzed the global asthma & COPD drugs market from four perspectives: Disease Type, Drug Class, Distribution Channel, and Region.
Disease Type Segmentation: Based on the disease type, global asthma & COPD drugs market is segmented into asthma and COPD. The asthma segment dominates the market with the largest revenue share because of a rise in asthma patients, increased consumption of cigarettes, and increased air pollution.
Drug Class Segmentation: Based on the drug class, global asthma & COPD drugs market is segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. The combination drugs segment dominates the market because of the growing use of drugs and medication combinations to treat various diseases.
Distribution Channel Segmentation: Based on the distribution channel, global asthma & COPD drugs market is segmented into hospital, retail, and online pharmacies. The hospital pharmacy segment dominates the market because of high patient footfall and the availability of advanced healthcare services.
Regional Growth Dynamics
Based on the region, global asthma & COPD drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates asthma & COPD drugs market with the largest revenue share. The increased number of asthma and COPD patients in this region is the major factor responsible for North America’s significant revenue share in the global market.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/asthma-copd-drugs-market/7909
Competitive Landscape
The major players operating in global asthma & COPD drugs market are:
- GlaxoSmithKline PLC
- Amgen, Inc.
- Abbott Laboratories
- Merck & Co. Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Novartis AG
- Hoffmann-La Roche Ltd
- Sanofi S.A.
- Teva Pharmaceuticals Industries Ltd.
- Vectura Group Plc.
- Dr. Reddy’s Laboratories
- Cipla Limited
- Mylan N.V.
- Glenmark Pharmaceuticals Limited
- Aurobindo Pharma Limited
Asthma & COPD drug market is slightly competitive, with several international players involved. Key market players are investing in technological advancements, R&D activities, mergers, and acquisitions to strengthen their market presence.
Recent developments:
- Verona reported positive results from its phase 3 ENHANCE-2 clinical trial of ensifentrine, which treats chronic obstructive pulmonary disease, in October 2022. (COPD). Ensifentrine is a product candidate with bronchodilator and anti-inflammatory properties in a single compound.
- Glenmark announced the novel fixed-dose combination (FDC) drug Indacaterol + Mometasone for patients with uncontrollable asthma in India in June 2022 under the brand Indamet.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL ASTHMA AND COPD DRUGS MARKET – ANALYSIS & FORECAST, BY DISEASE TYPE
- Asthma
- Chronic Obstructive Pulmonary Diseases (COPD)
Asthma And COPD Drugs Market TOC
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-7909
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse related reports:
Disposable Medical Devices Market by Product Type (Wound Management Products, Sterilization Supplies), Raw Material (Plastic Resins, Nonwoven Material), and End User (Hospitals and Home Healthcare) – Global Outlook & Forecast 2022-2030
Facial Injectables Market by Product (Botulinum Toxin [Botox], Collagen, and Hyaluronic Acid), by Application (Aesthetics & Therapeutics) and End User (Hospitals & Dermatologic Clinics) – Global Outlook and Forecast 2020-2030
Gene Therapy Market by Vector Type (Viral, Non-Viral), Delivery Type (Ex-Vivo, In-Vivo), Application (Oncology, Cardiology, Neurology), End-user (Hospitals, Ambulatory Centers)– Global Outlook & Forecast 2022-2030
Idiopathic Pulmonary Fibrosis Market by Drug Class (Tyrosine Kinase Inhibitors, Antifibrotic Agents), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2022-2030
Global Infectious Disease Diagnostics Market by Product (Instruments, Reagents), Technology (PCR, Immunodiagnostics), Disease Type (Hepatitis, HPV), End User (Hospitals & Clinics) – Global Outlook & Forecast 2022-2030
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
Contact:
Manan Sethi
Director, Market Insights
Email: sales@growthplusreports.com
256 Chapman Road
STE 105-4, Newark,
New Castle – 19702, USA
Phone no: +1 888 550 5009
Web: https://www.growthplusreports.com/